The Cooper Companies, Inc. (NASDAQ:COO) Stock Holdings Boosted by Congress Asset Management Co.

Congress Asset Management Co. boosted its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 0.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,247,184 shares of the medical device company’s stock after purchasing an additional 1,269 shares during the period. Congress Asset Management Co. owned approximately 0.63% of Cooper Companies worth $137,614,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Covestor Ltd raised its stake in shares of Cooper Companies by 305.9% in the 1st quarter. Covestor Ltd now owns 276 shares of the medical device company’s stock valued at $28,000 after acquiring an additional 208 shares in the last quarter. Innealta Capital LLC acquired a new stake in Cooper Companies in the 2nd quarter valued at approximately $25,000. Crewe Advisors LLC lifted its holdings in shares of Cooper Companies by 286.4% during the second quarter. Crewe Advisors LLC now owns 340 shares of the medical device company’s stock worth $30,000 after buying an additional 252 shares during the last quarter. Clearstead Trust LLC acquired a new stake in shares of Cooper Companies in the first quarter worth $36,000. Finally, Tortoise Investment Management LLC increased its position in Cooper Companies by 75.4% during the second quarter. Tortoise Investment Management LLC now owns 393 shares of the medical device company’s stock worth $34,000 after acquiring an additional 169 shares during the period. Institutional investors and hedge funds own 24.39% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Stifel Nicolaus reissued a “buy” rating and set a $115.00 target price (up from $110.00) on shares of Cooper Companies in a research report on Thursday, August 29th. Morgan Stanley raised their target price on Cooper Companies from $95.00 to $104.00 and gave the stock an “equal weight” rating in a research report on Tuesday, September 10th. Piper Sandler raised their price objective on shares of Cooper Companies from $115.00 to $120.00 and gave the stock an “overweight” rating in a report on Thursday, August 29th. Robert W. Baird increased their price target on shares of Cooper Companies from $118.00 to $125.00 and gave the stock an “outperform” rating in a research report on Thursday, August 29th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Cooper Companies in a research note on Thursday, August 29th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, Cooper Companies has a consensus rating of “Moderate Buy” and a consensus target price of $117.00.

Insider Transactions at Cooper Companies

In related news, COO Daniel G. Mcbride sold 114,992 shares of the stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $105.48, for a total value of $12,129,356.16. Following the sale, the chief operating officer now owns 44,696 shares in the company, valued at approximately $4,714,534.08. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CAO Agostino Ricupati sold 1,601 shares of the company’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $108.03, for a total transaction of $172,956.03. Following the completion of the sale, the chief accounting officer now directly owns 4,818 shares in the company, valued at approximately $520,488.54. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Daniel G. Mcbride sold 114,992 shares of the business’s stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $105.48, for a total transaction of $12,129,356.16. Following the completion of the transaction, the chief operating officer now owns 44,696 shares of the company’s stock, valued at $4,714,534.08. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 256,373 shares of company stock worth $27,637,427 in the last ninety days. Insiders own 2.00% of the company’s stock.

Cooper Companies Stock Down 0.5 %

NASDAQ COO traded down $0.48 on Thursday, reaching $104.72. The company had a trading volume of 101,137 shares, compared to its average volume of 1,122,496. The Cooper Companies, Inc. has a 1-year low of $77.01 and a 1-year high of $112.38. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.18 and a current ratio of 1.99. The company’s fifty day moving average is $106.34 and its 200-day moving average is $96.91. The firm has a market capitalization of $20.86 billion, a price-to-earnings ratio of 58.44, a price-to-earnings-growth ratio of 2.53 and a beta of 0.98.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings results on Wednesday, August 28th. The medical device company reported $0.96 EPS for the quarter, topping the consensus estimate of $0.91 by $0.05. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $997.30 million. Cooper Companies had a net margin of 9.45% and a return on equity of 9.08%. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.84 EPS. On average, research analysts forecast that The Cooper Companies, Inc. will post 3.65 earnings per share for the current fiscal year.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.